Sorry, but the harsh reality is that health research and care funds are limited and developing a vaccine is extremely expensive, and in many cases "iffy" proposition. Dollars are allocated where drug companies and/or the government will get the most return on investment. Both my husband and niece have been involved in health care research, through a university that gets grants from the government and drug companies. Promising projects are abandoned all the time because the money isn't available and/or the perceived demand is inadequate.

As for global reach, I think you are still talking about a relatively small percentage of the population, and the number of places that even recognize and treat MAI are not huge. The sad fact is that a lot of the world population is still worried about keeping babies alive to grow into adulthood, providing adequate food and safe water and vaccinating for contagious diseases. Problems like MAI are not even on their radar.

I'm not trying to be argumentative, just pointing out that in the face of scarce resources, things that are worthwhile to small parts of the population fall by the wayside. This is even true of subsets of "headline" diseases like cancer - the rare ones don't get the same research as common ones.

Sue